Comparação do uso de Solidago microglossus D.C e laserterapia de baixa intensidade para prevenção e para tratamento de mucosite oral em pacientes submetidos à radioterapia de cabeça e pescoço e/ou quimioterapia

Abstract

The oral mucositis is an adverse event of radiotherapy and/or high toxicity chemotherapy. The Solidago microglossus D.C. (Arnica) has been used for its antiseptic, analgesic, healing and anti-inflammatory properties. This study aimed to evaluate the uses of Arnica for oral mucositis prevention in patients submitted to radiotherapy for head and neck tumors treatment and/or high toxicity chemotherapy. The determination of the cytotoxicity index of the aqueous extract was measured in vitro. The oral mucosa was evaluated in days 0, 10 and 14 of patients in the groups: treated with lasertherapy (L, n=18), treated just with Arnica (A, n=24) and, treated with lasertherapy associated with Arnica (LA, n=4). It was considered significant p<0.05. It was determined IC50=90,74 μg/mL of Arnica’s aqueous extract in SCC-4 cells. The development of oral mucositis was associated with the type of treatment for oral mucositis prevention: L, A, and LA (χ2 = 24,72, p<0.0001). The level of oral mucositis had significant interaction with the type of prevention treatment [F(2) = 9.545, p<0.0001] and, within 14 days [F(2) = 11.995, p<0.0001]. The results obtained suggest which the use of Solidago microglossus D.C. (Arnica) can be an important therapeutic option for treatment with low-level laser therapy for oral mucositis prevention in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy.